Adalvo today reported successful results from a pivotal fasting bioequivalence study for Cariprazine capsules, a key milestone ahead of its upcoming DCP submission this month.
Cariprazine, based on the reference brand Reagila®, is the only approved antipsychotic shown to outperform a second-generation therapy, Risperidone.
The company is preparing for a Day-1 launch in major markets. The addition of Cariprazine strengthens Adalvo’s CNS portfolio and addresses unmet needs in schizophrenia treatment.
Global sales of Cariprazine reached $4.5 million in 2024, with a 3-year CAGR of 32%, reflecting steady growth potential for this generic therapy.
For licensing or partnership inquiries, contact Adalvo’s Business Development team.